| Abstrakt: |
Versapeutics Inc. has filed a patent application for a new antibody variant that targets the Wnt receptor Ryk. This receptor is involved in various cellular functions and is also implicated in pathologies such as spinal cord injuries, neuropathic pain, and cancer. The patent application describes isolated anti-Ryk antibodies that specifically bind to a Wnt-binding domain on Ryk, and these antibodies have shown promise in promoting axon regeneration and reducing neuropathic pain in animal models. The invention aims to provide improved antibodies with low immunogenic potential for use in human therapeutics, and the patent application includes methods for interfering with the interaction of Wnt and Ryk and for manufacturing medicaments for neurological diseases and cancer treatment. [Extracted from the article] |
